FDA Postpones PDUFA Date For Schering-Plough’s Bridion To Third Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency requires more time to analyze hypersensitivity study, firm says.
You may also be interested in...
Schering Plough’s Bridion Faces FDA Setback
Safety concerns render anesthesia injection “not approvable” in U.S.
Schering Plough’s Bridion Faces FDA Setback
Safety concerns render anesthesia injection “not approvable” in U.S.
Europe Likes Schering’s Bridion, But Not Takeda’s Rozerem
New opinion includes CHMP skepticism of insomnia drug.